Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: john who wrote (19)	3/1/1998 12:45:00 PM
From: aknahow	Read Replies (2) \| Respond to of 415

I am interested in Microcide and obtained a 1996 annual report sometime ago. After reading the report I lost interest. Does any information exist that lets shareholders know how the royalty agreements are structured? I am unable to feel that comfortable with a meaningful position when I can know if MCDE will receive 2% or 25% royalties on its three major "partnered" drugs. I am aware that the S.E.C. does not require disclosure nor do the auditors. For MCDE I really believe at this information is material. I hate not knowing it even when it may be incidental because major efforts are not "partnered" out.